Osteoarthritis of the knee
Conditions
Interventions
Bupivacaine liposome complex bupivacaine hydrochloride group (LB group):Bupivacaine Liposome Injection (20 ml:266 mg), Jiangsu Hengrui Pharmaceutical Co., Ltd. The drug in the test group was bupivacai
Ropivacaine combined with dexamethasone group (R group):Ropivacaine hydrochloride for injection (10 ml:100mg), Chenxin Pharmaceutical Co., Ltd. The control group was 0.5% ropivacaine 20 ml (containing
Sponsors
Dazhou Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.No gender restrictions, age 18~80 years old; 2.BMI 18.5~32.5 kg/m^2; 3.Elective unilateral total knee arthroplasty; 4.American Society of Anaesthesiologists (ASA) classification I-III; 5.Understand and voluntarily participate in the study and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1.Severe insufficiency of vital organs; 2.Revision or bilateral total knee arthroplasty; 3.Contraindications to nerve blocks; 4.Cognitive dysfunction; 5.Allergy to any of the study drugs; 6.History of chronic opioid usage; 7.Any other condition that the investigator considers inappropriate for participating in this trial; 8.Participation in a clinical trial of any other medicine within the last 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of moderate to severe pain on movement 48 h postoperatively; | — |
Secondary
| Measure | Time frame |
|---|---|
| Rest and movement pain numerical rating scale scores;Opioid dosage;Incidence of remedial analgesia after surgery;Quality of patient recovery after surgery;Postoperative adverse events such as nausea and vomiting; | — |
Countries
China
Contacts
Public ContactChao Liao
Dazhou Central Hospital
Outcome results
None listed